Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Excited to see our collaborative Dana-Farber Cancer Institute effort finally out in Nature Magazine. Led by Hugo Aerts and Simon Bernatz.
In this work, we identify radiographic Thymic Health, quantified from routine CT scans using deep learning, as a tumor-agnostic biomarker of immunotherapy outcomes.
Across a large real-world cohort of 3,476 patients treated with ICI, higher thymic health was consistently associated with improved progression-free and overall survival across multiple cancer types.
Biologically, thymic health reflects host immune competence and positively correlates with increased TCR diversity, and greater circulating and intratumoral T-cell abundance.
Together, these findings highlight a critical, often overlooked dimension of patient’s immune fitness, and suggest that integrating host-based biomarkers alongside tumor-centric features may better inform precision immuno-oncology.”
Title: Thymic health and immunotherapy outcomes in patients with cancer
Authors: Simon Bernatz, Vasco Prudente, Suraj Pai, Asbjørn K. Attermann, Alessandro Di Federico, Andrew Rowan, Selvaraju Veeriah, Lars Dyrskjøt, Leonard Nürnberg, Joao V. Alessi, Patrick A. Ott, Elad Sharon, Allan Hackshaw, Nicholas McGranahan, Christopher Abbosh, Raymond H. Mak, Danielle Bitterman, Mark Awad, Biagio Ricciuti, Charles Swanton, Mariam Jamal-Hanjani, Nicolai J. Birkbak, Hugo J. W. L. Aerts
Read The Full Article
Other articles about Immunotherapy on OncoDaily.